trial

ITI-007 (Lumateperone Tosylate) for Schizophrenia

NCTId NCT03817528
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 4 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2020-09-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
4 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-03-01
Primary completion
2020-09-23
Eligibility
MALE · 18 Years · 60 Years

Interventions & indications

Drugs
Lumateperone (Caplyta)

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Intra-Cellular Therapies, Inc.Collaborator

Investigators

1
Jeffrey A. Lieberman, MDPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
ITI-007 (Lumateperone Tosylate) for Schizophrenia — primary completion2020-09-23

Facts & assertions

4 sourced
Enrollment
4
Phase
PHASE2
Primary Completion Date
2020-09-23
Status
TERMINATED
relationships
The graph out of here
drug
Lumateperone (Caplyta)
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Intra-Cellular Therapies, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jeffrey A. Lieberman, MD
person